

Clinical trials of darbepoetin alfa

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
darbepoetin alfa vs placebo			
STAMINA-HeFT (Ghali) , 2008 [NCT00049985] n=162/157 follow-up: 27 weeks	darbepoetin alfa SC every 2 weeks for 1 year (target hemoglobin, 14.0+/-1.0 g/dL). versus placebo	Patients with symptomatic HF, left ventricular ejection fraction <or = 40% , and hemoglobin >or = 9.0 g/dL and <or = 12.5 g/dL	Parallel groups double blind
van Veldhuisen , 2007 [NCT00086086] n=110/55 follow-up: 27 weeks	darbepoetin alfa subcutaneously every 2 weeks for 26 weeks at a starting weight-adjusted dose of 0.75 mcg/kg or a fixed dose of 50 mcg versus placebo	Patients with chronic heart failure (>=3 months), left ventricular ejection fraction <= 40% , and Hb 9.0 to 12.5 g/dL	Parallel groups double blind
Ponikowski , 2007 [NCT00117234] n=19/22 follow-up: 27 weeks	Subcutaneous (SC) Darbepoetin Alfa versus subcutaneous placebo	patients with Symptomatic Congestive Heart Failure (CHF) and Anemia	Parallel groups double blind
Parissis , 2008 n=21/11 follow-up:	3-month darbepoetin alpha regimen at 1.5 microg/kg every 20 days plus oral iron versus placebo plus oral iron	CHF patients NYHA II-III, LV ejection fraction [EF] <40% , hemoglobin level <12.5 g/dL, serum creatinine level <2.5 mg/dL	
Parissis , 2009 n=30 follow-up:	3-month darbepoetin alfa regimen at 1.5 microg/kg every 20 days plus oral iron versus placebo plus oral iron	patients with CHF (LV ejection fraction [LVEF] <40% , hemoglobin <12.5 g/dl, and serum creatinine <2.5 mg/dl	
Kourea , 2008 n=21/20 follow-up:	3-month darbepoetin-alpha at 1.5 microg/Kg every 20 days plus iron orally versus placebo plus iron orally	CHF patients NYHA II-III; left ventricular ejection fraction <40% ; hemoglobin<12.5 g/dl; serum creatinine<2.5 mg/dl	double blind

More details and results :

- increasing hemoglobin concentration for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q301>

References

STAMINA-HeFT (Ghali), 2008:

Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. *Circulation* 2008;117:526-35 [[18195176](#)]

van Veldhuisen, 2007:

van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. *Eur Heart J* 2007;28:2208-16 [[17681958](#)]

Ponikowski, 2007:

Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol* 2007;49:753-62 [[17306703](#)]

Parissis, 2008:

Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, Kremastinos DT Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am Heart J* 2008;155:751.e1-7 [[18371487](#)]

Parissis, 2009:

Parissis JT, Kourea K, Andreadou I, Ikonomidis I, Markantonis S, Ioannidis K, Paraskevaidis I, Iliodromitis E, Filippatos G, Kremastinos DT Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 2009;103:1134-8 [[19361602](#)]

Kourea, 2008:

Kourea K, Parissis JT, Farmakis D, Paraskevaidis I, Panou F, Filippatos G, Kremastinos DT Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. *Eur J Cardiovasc Prev Rehabil* 2008;15:365-9 [[18525396](#)]

Entry terms: *tasoglutide*, *tasoglutide*,